What? When? Why?

Latest Happenings in Business World

Share on

Nov-2021

Global Conjugate Vaccine Market Size Worth USD 33.23 billion by 2026

Global Conjugate Vaccine Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Disease Indication, Type, Patient Stage, Pathogen Type & Region (North America, Europe, APAC, Latin America, Middle East and Africa) – Industry Forecast (2021 to 2026)

The size of the global conjugate vaccine market is forecasted to be growing at a CAGR of 16.34% from 2021 to 2026 and worth USD 33.23 billion by 2026 from USD 15.59 billion in 2021.

COVID-19 impact on the global conjugate vaccine market:

Except for lockdowns, the only means of control were limited to a series of mitigation measures such as self-distancing, the use of masks, travel restrictions, and avoidance of meetings, all of which are restrictive. As of 2021, reports indicate more than 110 million infected people and more than 2.5 million deaths; this high number of infections demands adding vaccines to existing countermeasures as the best hope against the pandemic. Emerging infectious diseases such as SARS- COVID- 19 virus threaten human health and global stability.

The potential of COVID-19 conjugate vaccine candidates and development and advancement in clinical evaluation under the trade name SOBERANA02 are paving the way for other conjugate antiviral vaccines.

KEY DRIVING FACTORS:

The rising prevalence of various infectious diseases and large population is predicted to drive the growth of the conjugate vaccines market. According to the World Health Organization (WHO), more than 350 million people have been vaccinated with the meningococcal A conjugate vaccine in the African continent. Furthermore, the increasing prevalence of meningococcal and pneumococcal infections is an essential factor that is predicted to contribute to the market's overall growth. According to the Centers for Disease Control and Prevention (CDC), around 420 total cases of meningococcal disease were reported in the United States. Furthermore, the increase in healthcare awareness and improvement in research and development will raise the number of people requiring conjugate vaccines.

According to the National Institutes of Health, high mortality and morbidity are due to diseases that vaccines can prevent. In 2012, 89% of the population in high-income countries had pneumococcal conjugate vaccines in their immunization schedule, while only 2.1% had pneumococcal conjugate vaccines in their immunization schedule among the total population of low-income countries. Spread and improvement in the healthcare industry contribute to the growth of the market.

MAJOR RESTRAINTS:

The complex production process of conjugate vaccines, significant investments for research and development, the unavailability of these vaccines in remote areas, and fraud and negligence due to the black market with high demand are expected to have a negative impact on the conjugate vaccine market.

KEY MARKET INSIGHTS:

Based on the type, the monovalent conjugate vaccine segment accounted for most of the market in the past. This dominant market share can be attributed to the high quality of vaccines and the knowledge of monovalent conjugate vaccines among healthcare professionals. On the other hand, the multivalent conjugate vaccine segment will have the fastest rising market growth during the analysis period, owing to improvements in technology and favorable government initiatives across the globe.
Based on the disease indication, the diphtheria-tetanus-pertussis segment dominated over all other segments. The contagious nature of respiratory tract infections and the high number of cases will be responsible for the growth of the DTP segment. In addition, the pneumococci segment is predicted to grow at the fastest rate, owing to a large number of the senior population.
Based on its pathogenicity, the bacterial conjugate vaccine held most of the market share due to the prevalence of bacterial disorders.
Based on region, in 2020, North America was the largest market for the conjugate vaccine during the forecast period and is likely to maintain its lead. Increased demand for pneumococcal, meningococcal, and other vaccines in the North American region is predicted to contribute to the overall market growth. On the other hand, the Asia-Pacific region is projected to be the fastest-growing region during the given period due to the increase in vaccination initiatives from organizations such as the World Health Organization in emerging economies.
The conjugate vaccine market consists of renowned national and international companies. Most of them constantly strive to compete with their competitors by launching innovative products.
The major players in the portable robotic exoskeleton market are Pfizer, Inc., Inc., GlaxoSmithKline plc, Merck and Company, CSL Limited, Biological E, Bharat Biotech, Neuron Biotech, Novartis AG, Sanofi Pasteur, Serum Institute of India. Biologique E. Limited and Bio-Med.

MARKET SEGMENTATION:

By Type: